文献速递耳科与耳神经

二甲双胍对糖尿病患者顺铂诱导耳毒性的影响

The Effects of Metformin on Cisplatin-Induced Ototoxicity in Diabetic Patients.
PubMed 文献 · Otolaryngol Head Neck Surg · 2024-10-26

这项回顾性病例对照研究纳入2000年1月1日至2018年12月31日接受顺铂治疗的72例糖尿病患者,按化疗期间是否使用二甲双胍分组。二甲双胍组按CTCAE和ASHA标准判定的听力损失比例均超过非二甲双胍组的两倍(CTCAE:54.4% vs 19.2%,P = .004;ASHA:62.2% vs 28.0%,P = .003)。作者认为二甲双胍未降低听力损失发生率,反而可能与风险增加相关。

要点

  • 72例糖尿病顺铂治疗患者中,46例使用二甲双胍、26例未使用。
  • 二甲双胍组CTCAE听力损失54.4% vs 非二甲双胍组19.2%(P = .004)。
  • 二甲双胍组ASHA听力损失62.2% vs 非二甲双胍组28.0%(P = .003)。

核心结论

  • 与临床前数据的预期相反,二甲双胍未降低接受顺铂患者的听力损失发生率,反而可能与风险增加相关。

研究设计与样本

  • 回顾性病例对照研究,纳入2000年1月1日至2018年12月31日在一家三级医疗中心听觉监测项目中登记的接受顺铂治疗的糖尿病患者,按化疗时是否使用二甲双胍分组。
  • 共72例符合纳入标准,其中46例化疗期间使用二甲双胍,26例未使用。

主要发现

  • 按CTCAE标准判定的听力损失比例:二甲双胍组54.4% vs 非二甲双胍组19.2%(P = .004)。
  • 按ASHA标准判定的听力损失比例:二甲双胍组62.2% vs 非二甲双胍组28.0%(P = .003)。
  • 多变量分析中,被认为可能是混杂因素的各项协变量均与结局无显著关联。

关键数值与推荐

  • 主要结局为按美国国家癌症研究所不良事件通用术语标准(CTCAE)定义的听力变化。
  • 次要耳毒性指标为按美国言语-语言-听力协会(ASHA)和TUNE标准判定的听力变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Ototoxicity is an important side effect of cisplatin. Recent animal and in vitro studies suggest metformin may protect hearing, though human studies are lacking. We report the first retrospective clinical study exploring the effects of metformin on cisplatin-induced ototoxicity. STUDY DESIGN: Retrospective case-control. SETTING: Tertiary-care center. METHODS: We reviewed all diabetic patients treated with cisplatin who were enrolled in an auditory monitoring program between January 1, 2000 and December 31, 2018. Patients were grouped according to their use of metformin at the time of chemotherapy. Demographics, oncologic diagnosis and treatment, and prior noise exposure were recorded. Audiometric thresholds were compared before and after chemotherapy. The primary outcome measure was a change in hearing as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). Secondary measures of ototoxicity included changes in hearing using the American Speech-Language-Hearing Association (ASHA) and TUNE criteria. RESULTS: Seventy-two diabetic patients met the inclusion criteria. Forty-six patients had taken metformin while on chemotherapy and 26 had not. The proportion of hearing loss as defined by both, CTCAE and ASHA criteria, was more than double in the metformin group relative to the nonmetformin group (CTCAE: 54.4% vs 19.2%, P = .004; ASHA: 62.2% vs 28.0%, P = .003). None of the potential covariates believed to be confounders were significantly associated with the outcome of multivariable analysis. CONCLUSION: Contrary to expectations from preclinical data, metformin did not reduce the incidence of hearing loss in patients receiving cisplatin and may, in fact, be associated with an increased risk.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Nader ME, Choi J, Hernandez M, et al. The Effects of Metformin on Cisplatin-Induced Ototoxicity in Diabetic Patients. Otolaryngol Head Neck Surg. 2024. PMID: 39460639. doi:10.1002/ohn.1032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。